GlassScriptPhysician profile
Edward M Soffen
NPI 1841200706
$49,554.05
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $4,215 · 2021: $16.78 · 2022: $470 · 2023: $427 · 2024: $2,313 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,500 · Travel and Lodging: $8,315 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,950 · Food and Beverage: $1,795 · Education: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,500.00 |
| Travel and Lodging | $8,315.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,950.00 |
| Food and Beverage | $1,794.72 |
| Education | $1,049.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $21,093.38 | 2024-2025 | Bioprotect Balloon Implant System |
| Augmenix, INC. | $15,636.06 | 2019 | |
| Boston Scientific Corporation | $11,034.18 | 2019-2025 | Spaceoar System, Spaceoar Vue System - 10ml |
| Novocure INC. | $470.66 | 2019-2025 | Optune, Optune Gio |
| Daiichi Sankyo INC. | $142.89 | 2022-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $130.33 | 2023-2025 | Pluvicto |
| Epizyme, INC. | $125.00 | 2022 | |
| Karyopharm Therapeutics INC. | $124.99 | 2023 | Xpovio |
| Amgen INC. | $102.31 | 2019-2022 | |
| Palette Life Sciences, INC. | $101.13 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $97.98 | 2023 | Opdivo |
| Progenics Pharmaceuticals, INC. | $69.21 | 2023-2025 | Pylarify |
| Isoray, INC | $63.17 | 2019-2023 | Brachytherapy Source |
| Bayer Healthcare Pharmaceuticals INC. | $53.35 | 2019-2021 | |
| Teleflex LLC | $40.45 | 2024-2025 | Barrigel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $35.14 | 2025 | Monoferric |
| Abbvie INC. | $33.73 | 2024-2025 | |
| Telix Pharmaceuticals | $33.20 | 2023-2025 | Illuccix |
| Siemens Medical Solutions USA, INC. | $26.71 | 2024 | Aria Radiation Therapy Management Software |
| Myovant Sciences INC. | $25.10 | 2022 | |
| Tempus Ai, INC | $23.81 | 2024 | Xt Cdx |
| Gt Medical Technologies, INC | $21.73 | 2022 | |
| Invivyd INC | $18.69 | 2025 | Pemgarda |
| Springworks Therapeutics, INC. | $18.63 | 2024 | Ogsiveo |
| Lilly USA, LLC | $16.56 | 2023 | Verzenio |
| Sumitomo Pharma America, INC. | $15.66 | 2023 | Orgovyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Soffen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.